20d40b1a-fbe0-4710-b0db-5c190e00addd
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.500
- G2M_CHECKPOINT+0.400
- PROTEIN_SECRETION+0.400
- WNT_BETA_CATENIN_SIGNALING+0.400
- E2F_TARGETS+0.300
- MITOTIC_SPINDLE+0.300
- MYC_TARGETS_V1+0.300
- MYC_TARGETS_V2+0.300
- NOTCH_SIGNALING+0.300
- PI3K_AKT_MTOR_SIGNALING+0.300
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.400
- IL6_JAK_STAT3_SIGNALING-0.400
- INFLAMMATORY_RESPONSE-0.400
- ANGIOGENESIS-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- ESTROGEN_RESPONSE_LATE-0.300
- TNFA_SIGNALING_VIA_NFKB-0.300
- XENOBIOTIC_METABOLISM-0.300
- BILE_ACID_METABOLISM-0.200
- COAGULATION-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 19EBA5E0-D299-4166-834A-256294572121 | — | — | 0.835 |
| 2 | TCGA-H4-A2HQ-01A-11R-A180-07 | — | — | 0.813 |
| 3 | MNG573 | — | — | 0.808 |
| 4 | B8B72B5C-536A-40E3-9E7F-95E7629874D3 | — | — | 0.798 |
| 5 | 0730F3DB-384B-43E6-A69F-BF3F7C2CCE78 | — | — | 0.793 |
| 6 | 61F5C72A-4DDB-4EDB-908A-B2856CAFD8BD | — | — | 0.782 |
| 7 | EED16435-CBED-4143-B5BA-C5C7C8510C3A | — | — | 0.779 |
| 8 | TCGA-34-5929-01A-11R-1820-07 | — | cohortSQ1 | 0.772 |
| 9 | 86379365-5FD2-4655-8B3C-B8E0EE25EE92 | — | — | 0.770 |
| 10 | 2DA298A9-AB20-4F9D-B83F-C7FC0679F889 | — | — | 0.769 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.400 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.300 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.300 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.100 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |